REPRO-MED Systems (KRMD) AI Stock Analysis

• Market Cap: $190.49M
• Dividend Yield: N/A
• Average Volume (3M): 140.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 19.57%
• EPS Growth: 61.81%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.01
• Shares Outstanding: 46,234,960
• 10 Day Avg. Volume: 176,801
• 30 Day Avg. Volume: 140,955
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: 4.36
• Enterprise Value/Gross Profit: 6.91
• Enterprise Value/Ebitda: -42.68
• 1Y Price Target: $4.88
• Price Target Upside: 18.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 59 Neutral
• Price Target: $4.50 ▲(9.22% Upside)

KRMD's overall score is driven by strong earnings call highlights and positive technical indicators, offset by weak financial performance and valuation concerns. The company's growth prospects are promising, but profitability and valuation issues remain significant risks.

Positive Factors

Financial Performance

KRMD delivered a strong quarter as it generated $10M in quarterly revenues for the first time and beat across the P&L, continuing to see material outperformance in its OUS markets.

Market Expansion

KRMD is expanding its products with a next-gen pump and a new flow controller designed to open new global markets and accelerate revenue growth, reinforcing its competitive advantage in the SCIg market.

Product Adoption

Early oncology trials have shown strong adoption, with 97% of patients preferring the system due to reduced pain and improved infusion efficiency, supporting the potential for broader uptake in the US.

Negative Factors

Competitive Pressures

There is wariness of the potential for competitive pressures to expand going forward.

REPRO-MED Systems Business Overview & Revenue Model

Company Description

REPRO-MED Systems, Inc. (KRMD) is a medical technology company specializing in the development and manufacturing of innovative medical devices and solutions for the healthcare sector. The company focuses primarily on the area of infusion therapy, providing products that improve the delivery of medications to patients with chronic conditions. Its core products include the proprietary infusion pump system, the FREEDOM60, designed for subcutaneous drug delivery, and other related accessories. REPRO-MED Systems operates in the medical device sector, targeting patients requiring home healthcare solutions, as well as healthcare providers and institutions.

How the Company Makes Money

REPRO-MED Systems generates revenue through the sale of its medical devices, primarily the FREEDOM60 infusion system and its associated accessories. The company's revenue model is based on direct sales to healthcare providers, distributors, and patients, as well as potential recurring revenue from consumable products related to its infusion systems. Key revenue streams include the initial sale of infusion pumps and ongoing sales of disposable components that require regular replacement. Additionally, partnerships with healthcare organizations and networks can enhance distribution capabilities and broaden market access, contributing to the company's overall earnings.

REPRO-MED Systems Financial Statement Overview

Summary

REPRO-MED Systems is experiencing revenue growth, but consistent losses and negative cash flows pose significant challenges. While the balance sheet shows a stable equity base and manageable debt levels, the company must address its operational inefficiencies to improve profitability and cash generation. Strategic cost management and revenue enhancement are crucial for future financial health.

Income Statement

The company shows a consistent growth trajectory in revenue with a 5% increase from the previous period to TTM. However, it struggles with profitability as evidenced by negative EBIT and net profit margins, indicating operational inefficiencies and high costs relative to revenue. The gross profit margin remains healthy, suggesting some control over direct costs.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.22, indicating prudent leverage. However, the return on equity is negative due to consistent net losses, which is a concern. The equity ratio of 60% indicates a solid capital structure with more equity financing, providing some financial stability.

Cash Flow

Cash flow analysis reveals challenges, as the company has negative operating cash flow and free cash flow, indicating potential liquidity issues. The free cash flow growth rate improved slightly, but remains negative, highlighting ongoing cash management challenges. The operating cash flow to net income ratio is unfavorable due to persistent losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.85M	33.65M	28.52M	27.90M	23.49M	24.18M
Gross Profit	23.27M	21.33M	16.71M	15.37M	13.77M	14.94M
EBITDA	-3.77M	-5.56M	-9.40M	-10.19M	-6.57M	1.61M
Net Income	-4.52M	-6.07M	-13.74M	-8.66M	-4.56M	-1.21M
Balance Sheet
Total Assets	25.52M	27.22M	28.46M	42.33M	41.29M	39.92M
Cash, Cash Equivalents and Short-Term Investments	8.05M	9.58M	11.48M	17.41M	25.33M	27.32M
Total Debt	3.47M	3.99M	4.45M	4.93M	604.14K	239.49K
Total Liabilities	8.99M	10.40M	8.11M	11.01M	4.79M	3.76M
Stockholders Equity	16.53M	16.81M	20.35M	31.33M	36.50M	36.16M
Cash Flow
Free Cash Flow	-2.17M	-1.62M	-5.71M	-8.21M	-4.69M	-1.80M
Operating Cash Flow	-682.14K	-319.72K	-4.89M	-5.40M	-4.32M	-743.32K
Investing Cash Flow	-1.53M	-1.33M	-814.60K	-2.80M	-366.17K	-1.04M
Financing Cash Flow	-194.03K	-248.53K	-218.87K	279.49K	2.71M	23.22M

REPRO-MED Systems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRMD, the sentiment is Positive. The current price of 4.12 is above the 20-day moving average (MA) of 3.62, above the 50-day MA of 3.47, and above the 200-day MA of 3.37, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 65.35 is Neutral, neither overbought nor oversold. The STOCH value of 91.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRMD.

REPRO-MED Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	79 Outperform	$187.03M	15.40	10.39%	2.05%	-16.64%	-13.64%
INFU	73 Outperform	$192.62M	39.29	9.39%	―	8.13%	1293.06%
KRMD	59 Neutral	$190.49M	―	-25.63%	―	19.57%	61.81%
Sector *	57 Neutral	£5.17B	4.93	-44.55%	2.32%	28.89%	-10.08%
RVP	52 Neutral	$23.20M	―	-25.89%	―	-16.05%	-195.28%
MLSS	47 Neutral	$48.98M	―	-88.36%	―	-9.13%	30.04%

REPRO-MED Systems Corporate Events

REPRO-MED Systems Holds Annual Shareholder Meeting

On May 14, 2025, REPRO-MED Systems held its Annual Meeting of Shareholders where key decisions were made regarding the company’s governance and financial oversight. Shareholders elected the proposed nominees to the board of directors, approved executive compensation on an advisory basis, and ratified the appointment of Cherry Bekaert LLP as the independent registered public accountants for the 2025 fiscal year.

The most recent analyst rating on (KRMD) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on REPRO-MED Systems stock, see the KRMD Stock Forecast page.